research use only

Elenbecestat BACE inhibitor

Name: Elenbecestat
Brand: Selleck Chemicals
SKU: S8600
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S8600

Elenbecestat (E2609) is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.

Chemical Structure

Molecular Weight: 437.44

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR MAO Beta Amyloid iGluR NMDAR P2 Receptor Trk receptor Serotonin Transporter Notch Norepinephrine Cannabinoid Receptor P-gp CaMK Opioid Receptor Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor CCK receptor
Related Products	LY2811376 LY2886721 Verubecestat (MK-8931) Trifluoroacetate Verubecestat (MK-8931) Lanabecestat (AZD3293) AZD3839 LX2343 BACE Antibody [D20J6] BACE1 Antibody [L19L22] Loganin Anti-BACE1 (Genentech anti-BACE1)

Chemical Information, Storage & Stability

Molecular Weight	437.44	Formula	C₁₉H₁₈F₃N₅O₂S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1388651-30-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	E2609			Smiles	CC1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(N=C4)C(F)F)F)N

Solubility

In vitro
Batch:

DMSO : 87 mg/mL (198.88 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 11 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.350mg/ml (9.94mM)	Taking the 1 mL working solution as an example, add 50 μL 87 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03055962	Completed	Healthy Participants	Eisai Co. Ltd.\|Eisai Inc.	February 14 2017	Phase 1
NCT02859207	Completed	Early Alzheimer''s Disease	Eisai Inc.	August 2016	Phase 1
NCT02322021	Terminated	Alzheimer Disease\|Dementia Alzheimer Type	Eisai Inc.\|Biogen	November 26 2014	Phase 2
NCT02222324	Completed	Healthy Subjects	Eisai Inc.	August 2014	Phase 1
NCT02207790	Completed	Healthy Subjects	Eisai Inc.	July 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):